Reduction of Advanced Liver Fibrosis by Short-Term Targeted Delivery of An Angiotensin Receptor Blocker to Hepatic Stellate Cells in Rats
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
There is no effective therapy for advanced liver fibrosis. Angiotensin type 1 (AT1) receptor blockers attenuate liver fibrogenesis, yet their efficacy in reversing advanced fibrosis is unknown. We investigated whether the specific delivery of an AT1 receptor blocker to activated hepatic stellate cells (HSCs) reduces established liver fibrosis. We used a platinum-based linker to develop a conjugate of the AT1 receptor blocker losartan and the HSC-selective drug carrier mannose-6-phosphate modified human serum albumin (losartan-M6PHSA). An average of seven losartan molecules were successfully coupled to M6PHSA. Rats with advanced liver fibrosis due to prolonged bile duct ligation or carbon tetrachloride administration were treated with daily doses of saline, losartan-M6PHSA, M6PHSA or oral losartan during 3 days. Computer-based morphometric quantification of inflammatory cells (CD43), myofibroblasts (smooth muscle α-actin [α-SMA]) and collagen deposition (Sirius red and hydroxyproline content) were measured. Hepatic expression of procollagen α2(I) and genes involved in fibrogenesis was assessed by quantitative polymerase chain reaction. Losartan-M6PHSA accumulated in the fibrotic livers and colocalized with HSCs, as assessed by immunostaining of anti-HSA and anti–α-SMA. Losartan-M6PHSA, but not oral losartan, reduced collagen deposition, accumulation of myofibroblasts, inflammation and procollagen α2(I) gene expression. Losartan-M6PHSA did not affect metalloproteinase type 2 and 9 activity and did not cause apoptosis of activated HSCs. Conclusion: Short-term treatment with HSC-targeted losartan markedly reduces advanced liver fibrosis. This approach may provide a novel means to treat chronic liver diseases. (Hepatology 2010.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationLiver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Self-citationLiver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Metadata
- Authors
- Moreno, M., Gonzalo, T., Kok, R. J., Sancho-Bru, P., van Beuge, M., Swart, J., Prakash, J., Temming, K., Fondevila, C., Beljaars, L., Lacombe, M., van der Hoeven, P., Arroyo, V., Poelstra, K., Brenner, D. A., Ginès, P., & Bataller, R.
- Venue
- Hepatology
- Published
- 2010-03
- Volume
- 51
- Issue
- 3
- Pages
- 942-952
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2004561550
- Cited by
- 132
- References
- 2
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction of Advanced Liver Fibrosis by Short-Term Targeted Delivery of An Angiotensin Receptor Blocker to Hepatic Stellate Cells in Rats. https://app.cochat.ai/papers/10.1002/hep.23419
- The paper
- Moreno, M., Gonzalo, T., Kok, R. J., Sancho-Bru, P., van Beuge, M., Swart, J., Prakash, J., Temming, K., Fondevila, C., Beljaars, L., Lacombe, M., van der Hoeven, P., Arroyo, V., Poelstra, K., Brenner, D. A., Ginès, P., & Bataller, R. (2010). Reduction of Advanced Liver Fibrosis by Short-Term Targeted Delivery of An Angiotensin Receptor Blocker to Hepatic Stellate Cells in Rats. Hepatology. https://doi.org/10.1002/hep.23419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.